Panagora Asset Management Inc. Has $2.74 Million Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Key Points

• Panagora Asset Management Inc. reduced its stake in Thermo Fisher Scientific by 24.0%, selling 1,738 shares to hold a total of 5,496 shares worth approximately $2.7 million as of its latest SEC filing.
• Multiple large investors have increased their positions in Thermo Fisher Scientific, including Vanguard Group Inc. (up 0.7%) and Charles Schwab Investment Management Inc. (up 4.1%).
• Analysts maintain a consensus rating of "Moderate Buy" for Thermo Fisher Scientific, with a price target of $593.00, reflecting confidence in the company's growth potential despite minor adjustments from some investment firms.

Panagora Asset Management Inc. reduced its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 24.0% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,496 shares of the medical research company's stock after selling 1,738 shares during the period. Panagora Asset Management Inc.'s holdings in Thermo Fisher Scientific were worth $2,735,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of TMO. Vanguard Group Inc. boosted its holdings in shares of Thermo Fisher Scientific by 0.7% in the first quarter. Vanguard Group Inc. now owns 33,479,957 shares of the medical research company's stock worth $16,659,627,000 after buying an additional 230,382 shares during the period. Charles Schwab Investment Management Inc. increased its position in shares of Thermo Fisher Scientific by 4.1% in the first quarter. Charles Schwab Investment Management Inc. now owns 2,925,591 shares of the medical research company's stock worth $1,455,774,000 after acquiring an additional 115,463 shares in the last quarter. Pictet Asset Management Holding SA increased its position in shares of Thermo Fisher Scientific by 7.2% in the first quarter. Pictet Asset Management Holding SA now owns 2,879,274 shares of the medical research company's stock worth $1,432,816,000 after acquiring an additional 193,378 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Thermo Fisher Scientific by 11.9% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,420,949 shares of the medical research company's stock worth $1,259,450,000 after acquiring an additional 257,462 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its position in shares of Thermo Fisher Scientific by 9.8% in the first quarter. Goldman Sachs Group Inc. now owns 2,419,617 shares of the medical research company's stock worth $1,204,002,000 after acquiring an additional 215,232 shares in the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP Gianluca Pettiti sold 400 shares of the firm's stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the sale, the executive vice president directly owned 22,367 shares of the company's stock, valued at approximately $10,735,712.66. This trade represents a 1.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CAO Joseph R. Holmes sold 385 shares of the firm's stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the sale, the chief accounting officer directly owned 2,319 shares in the company, valued at approximately $1,142,408.97. This represents a 14.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 29,666 shares of company stock valued at $13,982,763. 0.33% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of brokerages have commented on TMO. Wells Fargo & Company decreased their price objective on Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating for the company in a research report on Thursday, July 24th. Wall Street Zen raised shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research report on Saturday, August 30th. William Blair started coverage on shares of Thermo Fisher Scientific in a research report on Monday, August 18th. They issued an "outperform" rating for the company. Barclays increased their price objective on Thermo Fisher Scientific from $450.00 to $490.00 and gave the stock an "equal weight" rating in a report on Thursday, July 24th. Finally, UBS Group boosted their target price on Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a "neutral" rating in a research note on Thursday, July 24th. Sixteen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $589.38.

Thermo Fisher Scientific Stock Up 0.6%

Thermo Fisher Scientific stock traded up $2.71 during mid-day trading on Friday, hitting $492.20. 1,442,575 shares of the company's stock were exchanged, compared to its average volume of 1,624,930. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. The stock has a market cap of $185.86 billion, a P/E ratio of 28.47, a P/E/G ratio of 2.61 and a beta of 0.75. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $627.88. The stock has a 50 day moving average of $460.72 and a two-hundred day moving average of $453.43.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping the consensus estimate of $5.22 by $0.14. The firm had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business's quarterly revenue was up 2.9% on a year-over-year basis. During the same period in the prior year, the business posted $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Stockholders of record on Monday, September 15th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 9.95%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.